Additionally, some small molecules could also function in a synthetic lethal-like manner, where they exhibit potent responses against FGFR1 upregulated NSCLC by acting indirectly against additional pathways required for NSCLC tumor survival in this molecular context (e.g., PARP inhibitors). This evidence concerns the gene FGFR1 and non-small cell lung carcinoma.